(Adds shares in paragraph 2, details on disease in paragraph 3 and 4, background in paragraphs 5-7)
Sept 19 (Reuters) - The U.S. Food and Drug Administration has declined to approve Vanda Pharmaceuticals'
drug to treat stomach paralysis symptoms, the company said on Thursday.
Shares of the company fell about 14% to $4.26 in premarket trading.
Vanda was seeking the health regulator's nod for the drug tradipitant to treat gastroparesis, a condition characterized by delayed gastric emptying.
The disease is associated with symptoms such as severe nausea, vomiting, and difficulty finishing a normal meal.
Vanda licensed tradipitant from Eli Lilly and is also studying it for motion sickness.
The health regulator had imposed a partial clinical hold on tradipitant, preventing trials longer than 12 weeks.
The company plans to submit a separate application for the drug to prevent vomiting in motion sickness later this year.
(Reporting by Sriparna Roy in Bengaluru; Editing by Abinaya Vijayaraghavan)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。